Incyte NASDAQ: INCY is counting on a pipeline of cancer and immunology treatments, along with potential acquisitions, to support growth after JAKAFI loses exclusivity, executives said at the Jefferies Global Healthcare Conference in London.
Incyte NASDAQ: INCY is counting on growth from its existing medicines and a pipeline of late-stage treatments to support the company after JAKAFI loses exclusivity at the end of 2028, executives said at the UBS Global Biopharma Conference in London.
Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
Eurizon Capital SGR S.p.A. decreased its position in Incyte Corporation (NASDAQ: INCY) by 13.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 178,265 shares of the biopharmaceutical company's stock after selling 26,520 shares during the quarter. Eurizon Capital SGR S.p.A. owned
Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of growth after 2029.